Delving into the Latest Updates on Xiangbei Weierman Pharmaceutical Co., Ltd. with Synapse

Overview

1.比较试验药注射用阿莫西林钠克拉维酸钾（7:1，每日两次给药）用于（非复杂性）急性肾盂肾炎与对照药注射用阿莫西林钠克拉维酸钾（5:1，每日三次给药）的疗效。 2.探索注射用阿莫西林钠克拉维酸钾（7:1）用于（非复杂性）急性肾盂肾炎治疗的远期疗效（临床复发、细菌复发），为后期确证性临床研究的设计提供科学依据。

[Translation]

1. To compare the efficacy of the experimental drug amoxicillin sodium clavulanate potassium injection (7:1, twice daily) for (uncomplicated) acute pyelonephritis with the control drug amoxicillin sodium clavulanate potassium injection (5:1, three times daily). 2. To explore the long-term efficacy (clinical recurrence, bacterial recurrence) of amoxicillin sodium clavulanate potassium injection (7:1) for the treatment of (uncomplicated) acute pyelonephritis, and provide a scientific basis for the design of subsequent confirmatory clinical studies.

Start Date10 Feb 2023

Sponsor / Collaborator

Xiangbei Weierman Pharmaceutical Co., Ltd.

100 Clinical Results associated with Xiangbei Weierman Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Xiangbei Weierman Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Xiangbei Weierman Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Xiangbei Weierman Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data